Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry.
Ladi-Seyedian SS, Ghoreifi A, Konety B, Pohar K, Holzbeierlein JM, Taylor J, Kates M, Willard B, Taylor JM, Liao JC, Kaimakliotis HZ, Porten SP, Steinberg GD, Tyson MD, Lotan Y, Daneshmand S, Blue Light Cystoscopy With Cysview Registry Group. Ladi-Seyedian SS, et al. Among authors: kaimakliotis hz. Cancers (Basel). 2024 Mar 24;16(7):1268. doi: 10.3390/cancers16071268. Cancers (Basel). 2024. PMID: 38610946 Free PMC article.
Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers.
Reike MJ, de Jong JJ, Bismar TA, Boorjian SA, Mian OY, Wright JL, Dall'Era MA, Kaimakliotis HZ, Lotan Y, Boormans JL, Black PC, Gibb EA. Reike MJ, et al. Among authors: kaimakliotis hz. Urol Oncol. 2024 Jun;42(6):177.e5-177.e14. doi: 10.1016/j.urolonc.2024.01.027. Epub 2024 Mar 12. Urol Oncol. 2024. PMID: 38480079
Corrigendum to "Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes" [Eur. Urol. Focus (2023)].
Linehan J, Gottlieb J, Woldu SL, Labbate C, Rose K, Sexton W, Kaimakliotis H, Jacob J, Dickstein R, Nieder A, Bjurlin M, Humphreys M, Ghodoussipour S, Quek M, O'Donnell M, Eisner BH, Feldman AS, Matin SF, Lotan Y, Murray KS. Linehan J, et al. Among authors: kaimakliotis h. Eur Urol Focus. 2024 Jan;10(1):211. doi: 10.1016/j.euf.2023.08.006. Epub 2023 Aug 26. Eur Urol Focus. 2024. PMID: 37640582 No abstract available.
First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors.
Jacob JM, Woldu SL, Linehan J, Labbate C, Rose KM, Sexton WJ, Tachibana I, Kaimakliotis H, Nieder A, Bjurlin MA, Humphreys M, Ghodoussipour SB, Quek ML, Johnson B, O'Donnell M, Eisner BH, Feldman AS, Murray KS, Matin SF, Lotan Y, Dickstein RJ. Jacob JM, et al. Among authors: kaimakliotis h. Urol Oncol. 2024 Jan;42(1):20.e17-20.e23. doi: 10.1016/j.urolonc.2023.07.004. Epub 2023 Jul 28. Urol Oncol. 2024. PMID: 37517898
Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes.
Linehan J, Gottlieb J, Woldu SL, Labbate C, Rose K, Sexton W, Kaimakliotis H, Jacob J, Dickstein R, Nieder A, Bjurlin M, Humphreys M, Ghodoussipor S, Quek M, O'Donnell M, Eisner BH, Feldman AS, Matin SF, Lotan Y, Murray KS. Linehan J, et al. Among authors: kaimakliotis h. Eur Urol Focus. 2023 Nov;9(6):1052-1058. doi: 10.1016/j.euf.2023.05.012. Epub 2023 May 30. Eur Urol Focus. 2023. PMID: 37263827
The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma.
Kaimakliotis HZ, Tachibana I, Woldu S, Labbate C, Jacob J, Murray K, Rose K, Sexton W, Dickstein R, Linehan J, Nieder A, Bjurlin M, Humphreys M, Ghodoussipour S, Quek M, O'Donnell M, Eisner BH, Matin SF, Lotan Y, Feldman AS. Kaimakliotis HZ, et al. Urol Oncol. 2023 Sep;41(9):387.e1-387.e7. doi: 10.1016/j.urolonc.2023.04.010. Epub 2023 May 26. Urol Oncol. 2023. PMID: 37246135
Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease.
Rose KM, Murray KS, Labbate C, Woldu S, Linehan J, Jacob J, Kaimakliotis H, Dickstein R, Feldman A, Matin SF, Lotan Y, Humphreys MR, Sexton WJ. Rose KM, et al. Among authors: kaimakliotis h. Eur Urol Focus. 2023 Sep;9(5):807-812. doi: 10.1016/j.euf.2023.03.016. Epub 2023 Apr 12. Eur Urol Focus. 2023. PMID: 37059620 Review.
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.
Hahn NM, O'Donnell MA, Efstathiou JA, Zahurak M, Rosner GL, Smith J, Kates MR, Bivalacqua TJ, Tran PT, Song DY, Baras AS, Matoso A, Choi W, Smith KN, Pardoll DM, Marchionni L, McGuire B, Grace Phelan M, Johnson BA 3rd, O'Neal T, McConkey DJ, Rose TL, Bjurlin M, Lim EA, Drake CG, McKiernan JM, Deutsch I, Anderson CB, Lamm DL, Geynisman DM, Plimack ER, Hallman MA, Horwitz EM, Al-Saleem E, Chen DYT, Greenberg RE, Kutikov A, Guo G, Masterson TA, Adra N, Kaimakliotis HZ. Hahn NM, et al. Among authors: kaimakliotis hz. Eur Urol. 2023 Jun;83(6):486-494. doi: 10.1016/j.eururo.2023.01.017. Epub 2023 Jan 28. Eur Urol. 2023. PMID: 36717286 Clinical Trial.
82 results